Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Johannesburg Stock Exchange  >  Aspen Pharmacare Holdings Limited    APNJ   ZAE000066692

 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Johannesburg Stock Exchan…
02/13/2017 02/14/2017 02/15/2017 02/16/2017 02/17/2017 Date
313.73 311.2 309.53 295.58 288.2 Last
1064349 775768 496417 1798704 1599712 Volume
+1.99% -0.81% -0.54% -4.51% -2.50% Change
Financials ( ZAR)
Sales 2017 44 684 M
EBIT 2017 10 989 M
Net income 2017 7 528 M
Debt 2017 39 345 M
Yield 2017 1,00%
Sales 2018 49 290 M
EBIT 2018 12 694 M
Net income 2018 9 016 M
Debt 2018 30 458 M
Yield 2018 1,18%
P/E ratio 2017 17,52
P/E ratio 2018 14,90
EV / Sales2017 3,83x
EV / Sales2018 3,29x
Capitalization 131 828 M
More Financials
Company
Aspen Pharmacare Holdings Ltd. engages in the manufacture and supply of branded and generic pharmaceutical products.The firm operates through the following segments: International, South Africa, Asia Pacific, and Sub-Saharan Africa.Its products include anaesthetics, analgesics, antiretrovirals,... 
Sector
Pharmaceuticals
Calendar
03/08Earnings Release
More about the company
Surperformance© ratings of Aspen Pharmacare Holdings
Trading Rating : Investor Rating :
More Ratings
Latest news on ASPEN PHARMACARE HOLDINGS
01/30 ASPEN’S RESPONSE TO GUARDIAN A : 28 January 2017
01/12 ASPEN PHARMACARE : GSK confirms closure of agreement to divest non-core assets t..
01/05 ASPEN PHARMACARE : GSK confirms closure of agreement to divest non-core assets t..
01/03 ASPEN PHARMACARE : GSK confirms closure of agreement to divests non-core assets ..
01/03 GLAXOSMITHKLINE : GSK Confirms Closure of Agreement to Divests Non-Core Assets t..
2016 ASPEN PHARMACARE HOLDINGS LIMITED : ex-dividend day for annual dividend
2016 ASPEN PHARMACARE : Will Aspen bide its time now?
2016 TOP NEWS : GlaxoSmithKline Sells Entire Aspen Stake For GBP477 Million
2016DJGLAXOSMITHKLINE : to Sell Remaining 6.2% Stake in Aspen Pharmacare
2016 GLAXOSMITHKLINE : To Sell Entire 6.2% Stake In Aspen Pharmacare
More news
Sector news : Generic Pharmaceuticals
08:25aDJASTRAZENECA : licenses Cancer Drug Zoladex to TerSera for the US, Canada
02/17DJSHIRE : Files 8K - Other Events
02/17 European shares retreat after week of gains; Allianz rallies after update
02/17 ASTRAZENECA : Top AstraZeneca shareholder Woodford adds to stake, bullish on out..
02/17DJROCHE : U.S. Obtains Records in Lobbyist Probe -- WSJ
More sector news : Generic Pharmaceuticals
Latest Tweets
02/15Aspen Pharmacare $APNHY Downgraded to Hold at Zacks Investment Research  
02/15Aspen Pharmacare downgraded by Zacks Investment Research to hold.  
2016ASPEN PHARMACARE UNSP ADR EACH REP 1 upgraded by Zacks Investment Research to.. 
2016Neurim Pharmaceuticals Grants Aspen Pharmacare Australia Marketing Rights For.. 
2016On & Massmart's Kuseni Dlamini & Deloitte's Anthony Smith discuss t.. 
More tweets
Qtime:43
News from SeekingAlpha
2016 Wobbles Aside, Small Pharma Shares Broadly On The Up In 2015
2015 Sector's Smaller Players Show The Way
2015 OPPORTUNITIES AND RISKS IN THE BIOTE : 2 Companies In South Africa
2015 SEEKING ALPHA'S BIOTECH WEEKLY : Deeper Looks At Orexigen, Pharmacyclics, And Ac..
2015 WALL STREET BREAKFAST : Japan Marches Higher As Nikkei Breaches 19,000
Advertisement
Chart ASPEN PHARMACARE HOLDINGS
Duration : Period :
Aspen Pharmacare Holdings  Technical Analysis Chart | APNJ | ZAE000066692 | 4-Traders
Full-screen chart
Technical analysis trends ASPEN PHARMACARE ...
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Average target price 353  ZAR
Spread / Average Target 22%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Stephen Bradley Saad Group Chief Executive Officer & Executive Director
Douglas Dlamini Non-Executive Chairman
Michael Guy Attridge Executive Director & Group Deputy CEO
Roy Cecil Andersen Lead Independent Non-Executive Director
John Frederick Buchanan Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ASPEN PHARMACARE HOLDI..1.60%10 094
OTSUKA HOLDINGS CO LTD2.26%25 737
SUN PHARMACEUTICAL IND..7.05%24 168
ONO PHARMACEUTICAL CO...-1.68%13 131
SHANGHAI FOSUN PHARMAC..8.17%8 745
TAISHO PHARMACEUTICAL ..-3.91%7 450
More Results